Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial

SEOUL, South Korea, May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd. , a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical trial of its investiga...

2025-05-01 08:00 3312

Gedeon Richter: Medical Treatment of Endometriosis with a progressive approach

PRAGUE and BUDAPEST, Hungary, April 30, 2025 /PRNewswire/ -- Modern medical treatment options for endometriosis were among the main topics at the SEUD Congress (Society of Endometriosis and Uterine Disorders) held in Prague between 24-26 April, where a highly successful sympos...

2025-04-30 19:00 2566

Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting

SUZHOU, China, April 30, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American Association for Cancer Research (AACR) Annual Meetin...

2025-04-30 10:35 3666

Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

SAN FRANCISCO and SUZHOU, China, April 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2025-04-30 08:00 3742

Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong

SHANGHAI, April 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Department of Health of the...

2025-04-30 07:45 3181

Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

* Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations * Henlius to receive $31 million upfront, and up to $270 million in milestones SHANGHAI, April 29, 2025 /PRNewswire/ -- On April 29, 2025, Shanghai Henlius Biot...

2025-04-29 23:39 4094

Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

2025-04-29 23:38 3446

Metabolon Launches Microbiome Research Solution Combining New Microbiome Panel, Metagenomics Sequencing, and Multiomics Bioinformatics Tools

The combination of metagenomics and metabolomics data, integrated within an intuitive bioinformatics platform, enables deeper microbiome insights than possible with either approach individually MORRISVILLE, N.C., April 29, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing met...

2025-04-29 21:00 2108

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation from Committee for Medicinal Products for Human Use (CHMP) from February 2025 EU approval is b...

2025-04-29 14:00 2840

Comac Medical Announces New Leadership Appointments and International Expansion

Leadership transition and strategic growth initiatives mark the next phase of Comac Medical's development under EdgeCap Partners. SOFIA, Bulgaria, April 28, 2025 /PRNewswire/ -- Comac Medical, a leading full-service Contract Research Organization (CRO) in Central and Eastern Europe, announced t...

2025-04-28 16:00 2983

2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs

SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...

2025-04-28 08:00 2651

Everest Medicines Announces the "B" Marker Removal from Company's Stock Code, Effective May 2, 2025

SHANGHAI, April 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the "B" marker will cease to be...

2025-04-28 07:30 2577

Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality

SHANGHAI and HONG KONG, April 26, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hem...

2025-04-26 08:30 4625

Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer

SAN FRANCISCO and SUZHOU,China, April 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...

2025-04-26 08:00 6420

Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting

CHENGDU, China, April 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held inChicago from May 30 to June 3. Resu...

2025-04-24 13:17 3668

Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025

SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hem...

2025-04-24 10:26 4033

Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU,China, April 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2025-04-24 07:00 4765

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 mg doses. - ASC30 oral once-daily tablet also demonstrated a 4.5% placebo-adjusted mean body we...

2025-04-23 07:30 3634

Tianlong Showcases Innovation at Prestigious International Biomedical Forum in Kazakhstan

KARAGANDA, Kazakhstan, April 22, 2025 /PRNewswire/ -- Tianlong Science and Technology is honored to have been invited to speak at the "International Biomedical Forum: Researches and Innovations", held on April 17–18, 2025, at Karaganda Medical University inKazakhstan. In addition to presenting at...

2025-04-22 19:31 2941

Tianlong Showcases Innovation at Prestigious International Biomedical Forum in Kazakhstan

Docquity and AstraZeneca's Patient Support Program Educates Tens of Thousands in Thailand

* OAZisCare, digitally powered by DocquityCare, has advanced patient education and adherence for cancer care and RSV vaccines since 2024 * The collaboration helps tackle Southeast Asia's healthcare needs, with 85.7% of doctors noting immunization rates could improve with patient support (Do...

2025-04-22 11:00 5663

1 ... 43 44 454647 48 49 ... 184